论文部分内容阅读
目的 探讨Fas、FasL在正常卵巢和卵巢浆液性肿瘤组织中的表达及其临床意义。方法 2 0 0 0年 3月至 2 0 0 1年 1月中国医科大学附属第二医院等应用免疫组化法检测Fas、FasL在 5 6例卵巢浆液性肿瘤及 8例正常卵巢组织新鲜标本中的表达。结果 Fas在卵巢浆液性癌 (OSC)中的阳性表达率为 39 5 % ,明显低于交界性肿瘤 (77 8% )、良性肿瘤组织 (77 8% )及正常卵巢组织 (75 0 % ) ,差异有显著性意义 (P <0 0 5 )。FasL在OSC中的阳性表达率为 78 9% ,明显高于交界性肿瘤 (4 4 4 % )、良性肿瘤组织 (33 3% )及正常卵巢组织 (37 5 % ) ,差异有显著性意义 (P <0 0 5 )。卵巢浆液性癌中 ,Fas、FasL表达与临床分期相关 (P <0 0 5 ) ,与其他生物学特征无关 (P >0 0 5 )。结论 Fas在卵巢浆液性癌中表达下调 ,FasL在卵巢浆液性癌中过表达。
Objective To investigate the expression of Fas and FasL in normal ovarian and ovarian serous tumors and their clinical significance. Methods From March 2000 to January 2001, the Second Affiliated Hospital of China Medical University and other immunohistochemical detection of Fas, FasL in 56 cases of ovarian serous tumors and 8 cases of normal ovarian tissue fresh specimens expression. Results The positive rate of Fas in ovarian serous carcinoma (OSC) was 39.5%, which was significantly lower than that in borderline tumors (77.8%), benign tumor tissues (77.8%) and normal ovarian tissues (75.0%), The difference was significant (P <0 05). The positive rate of FasL in OSC was 78.9%, which was significantly higher than that in borderline tumors (44.4%), benign tumor tissues (33.3%) and normal ovarian tissues (37.5%) P <0 0 5). In ovarian serous carcinoma, the expression of Fas and FasL was correlated with clinical stage (P <0.05), but not with other biological characteristics (P> 0.05). Conclusion Fas is down-regulated in ovarian serous carcinoma and FasL is overexpressed in serous ovarian carcinoma.